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Abstract
The primary purpose of this article is to document whether demographic, clinical, regimen-related,
intrapersonal, and interpersonal factors predict medication non-adherence for vasculitis patients. A
secondary purpose is to explore whether adherence varies by medication type and whether patients
experienced drug-related side effects. Vasculitis patients (n=228) completed online baseline and 3-
month follow-up surveys. Demographic (age, gender, education, race, marital status, and
insurance status), clinical (perceived vasculitis severity, disease duration, vasculitis type, and
relapse/remission status), regimen-related (experience of side effects), intrapersonal (depressive
symptoms), and interpersonal (adherence-related support from family and friends) factors were
measured at baseline. Medication non-adherence was assessed at follow-up using the Vasculitis
Self-Management Survey medication adherence sub-scale (α=0.89). Variables that significantly
correlated (p<0.05) with non-adherence were included in a linear regression model to predict non-
adherence. Younger age (r=−0.23, p<0.001), female sex (r=0.16, p<0.05), experience of side
effects (r=0.15, p<0.05), and more depressive symptoms (r=0.22, p< 0.001) were associated with
more medication non-adherence, In the regression model, younger age (β=−0.01, p=0.01) and
more depressive symptoms (β=0.01 p=0.02) predicted worse adherence. For six out of eight
vasculitis medication types, patients who experienced side effects were less adherent than patients
who did not experience side effects. Multiple factors are associated with medication non-
adherence for vasculitis patients. Providers should discuss medication adherence and drug-related
side effects with vasculitis patients. Providers may want to particularly target younger patients and
patients with clinical signs of depression.
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Because medication non-adherence has been linked with negative clinical sequelae across a
broad range of chronic diseases [1], researchers have attempted to document what factors
predict non-adherence. Overall, the results lend support for a social ecological view of
adherence [2], in which patients’ medication-taking behaviors are nested within several
spheres of influence, which include but are not limited to: (a) clinical characteristics of the
disease, (b) aspects of the regimen, (c) intrapersonal characteristics and demographic
variables [3], and (d) interpersonal influences such as social support and quality of the
patient-provider relationship.
Social ecological models use concentric circles to depict the multiple levels of influence that
affect patient self-management behaviors such as medication adherence (Fig. 1) [4, 5].
Patient-level factors, such as knowledge and medication beliefs, are included in the
innermost circle. Interpersonal influences are typically represented by the next circle.
Moving outward, each additional circle represents more macro-level influences, with the
circle most distant to the patient often representing policy level influences such as health
insurance policies. Ecological models provide a logical way to organize the many factors
that affect patient medication adherence.
Relatively few studies have examined medication adherence for chronic inflammatory
rheumatic diseases [6–12], Only two studies, the Vasculitis Self-Management (VSM) study
and the Accessing Social Support in Symptom Treatment (ASSIST) study, have focused
specifically on vasculitis [13–15]. The VSM study used a cross-sectional study design to
examine barriers to performing various self-management behaviors, including medication
adherence, in a sample (n=202) of patients with small vessel vasculitis [e.g., Granulomatosis
with polyangiitis (GPA, formerly known as Wegener’s), microscopic polyangiitis (MPA),
eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss)]. Five
barriers were associated with worse medication adherence. The first two barriers were
disruptions to the patient’s daily routine and forgetting to take medication. The other three
barriers were related to the complexity of the medication regimen and included: (1) a large
number of medications, (2) difficult medication instructions, and (3) a complicated dosing
schedule. The second vasculitis-specific study, ASSIST, used a longitudinal study design to
examine whether social support and conflicting medication information from different
sources (e.g., physicians and the Internet) was associated with worse medication adherence.
Data were collected in 2008, and the ASSIST sample (n=228) included patients with any
form of vasculitis. Carpenter and colleagues [15] documented that vasculitis patients who
received conflicting information about their medications from different sources at baseline
were less adherent at 3-month follow-up. The study did not collect data about which sources
provided patients with conflicting information; thus, it is unknown whether professional
sources, such as two physicians, or informal sources, such as the Internet or other vasculitis
patients, provided patients with conflicting medication information. Regarding support,
Carpenter and colleagues demonstrated that physician support increased vasculitis patients’
adherence self-efficacy, and consequently predicted better medication adherence [15]. The
positive relationship between physician support, self-efficacy, and medication adherence
was confirmed by Pepper and associates using an alternative measure of medication
adherence [14]. Pepper et al. also found that adherence-related support from vasculitis
patients’ partners was significantly associated with greater adherence; however, the
relationship between partner support and adherence became insignificant after adjusting for
various demographic and clinical factors. Taken together, the results from VSM and
ASSIST suggest that both regimen-related (i.e., treatment complexity) and interpersonal
(i.e., social support) factors are related to medication adherence for vasculitis patients; yet,
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no study has taken a more holistic approach to examining the medication adherence of
vasculitis patients.
Studies with other rheumatic conditions, including gout, lupus, and rheumatoid arthritis
(RA), offer some guidance about additional factors that may affect vasculitis medication
adherence. In a review of RA patient adherence to disease-modifying anti-rheumatic drugs,
Salt and colleagues concluded that age, patient self-efficacy, patient beliefs about
medications, and interpersonal factors, including patient–provider relationship and social
support, influence medication adherence [7]. Additionally, experience of side effects [12,
16, 17], non-White race [17, 18], fewer years of education [17], taking fewer medications
[8], fewer comorbid conditions [19, 20], medication type [6, 20], and fewer visits to a health
care provider [12, 20] have been associated with worse adherence.
The objective of this study is to provide a more comprehensive understanding of predictors
of medication adherence for vasculitis patients. A broad range of factors, including
demographic, clinical, regimen-related, intrapersonal, and interpersonal influences, are
examined in relation to patient medication adherence at 3-month follow-up. Specific factors
were chosen based on their association with medication adherence in previous empirical
studies and represent multiple levels (intrapersonal, interpersonal) of the social ecological
framework. Additionally, we examine whether medication adherence varies as a function of
medication type and experience of medication side effects.
Materials and methods
Overview
All data were collected as part of the ASSIST Study, which was a longitudinal,
observational study that evaluated medication management issues for vasculitis patients. The
ASSIST Study consisted of two on-line questionnaires administered 3 months apart.
Because vasculitis patients’ medication regimens frequently change due to medication
intolerance or ineffectiveness [21], we limited our follow-up period to 3 months in order to
minimize the number of potential medication regimen changes. Eligible patients had a self-
reported diagnosis of vasculitis, were at least 18 years of age, were able to read and write in
English, had Internet access, and were taking at least one medication to treat their vasculitis.
This Institutional Review Board at the University of North Carolina at Chapel Hill approved
this study.
Sample
A total of 253 patients were eligible. Of these, we recruited 106 participants for the ASSIST
Study by distributing study information to attendees at a vasculitis patient conference (n=39)
and mailing physician-diagnosed vasculitis patients who were part of the Glomerular
Disease Collaborative Network (n=38) and prior vasculitis studies (n=29). We also
contacted members of vasculitis support groups and posted announcements on vasculitis
websites, in patient newsletters, and on patient list serves, which yielded an additional 147
eligible and interested participants. Participants recruited through the vasculitis conference,
support groups, newsletters, and list serves had a self-reported vasculitis diagnosis.
Carpenter and colleagues [15] provide a more thorough description of recruitment
procedures.
Of the 253 eligible patients, 232 (91.7 %) completed the 1-h baseline questionnaire. Reasons
for non-completion included never responding to study correspondence (n=7), technical
issues (n=7), or being too sick (n=4) or too busy (n=3) to participate. When compared with
completers, non-completers were not significantly different in terms of gender or self-
reported vasculitis type.
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Only 4 of the 232 participants were lost to follow-up, resulting in a retention rate of 98.2 %.
Participants who completed both questionnaires received a $10 gift card.
Measures
The baseline survey contained measures of demographic, regimen-related, clinical,
intrapersonal and interpersonal variables. The 3-month follow-up questionnaire contained
the medication non-adherence measure.
Demographic characteristics—Participants answered one item each about gender, race
(recoded as white vs. nonwhite), age, education (in years), health insurance status (insured
vs. not insured), and marital status (recoded as married vs. unmarried).
Regimen factors—Patients indicated whether they were currently taking any of the
following eight medications: cyclophosphamide (Cytoxan), steroids (Prednisone,
Methylprednisolone), co-trimoxazole (Bactrim), azathioprine (Imuran), cyclosprin,
methotrexate (Trexall, Rheumatrex), mycophenolate mofeitil (Cellcept), and rituximab
(Rituxan). For each medication, patients indicated whether they had experienced any side
effects related to that medication (yes/no). A total side effects score was calculated by
summing the number of yes responses; responses could range from 0 to 8.
Clinical factors—Patients responded to four clinical questions: (1) vasculitis type
[recoded as granulomatosis with polyangiitis (GPA) vs. other], (2) disease status (recoded as
currently experiencing a flare/relapse or not currently experiencing a flare/relapse), (3)
disease duration or how long they had been diagnosed with vasculitis, and (4) perceived
disease severity, which was measured on a scale from 1=“not at all severe” to
10=“extremely severe.”
Intrapersonal factors—Depressive symptoms were measured with the 20-item Center
for Epidemiologic Studies Depression Scale (CES-D) [22]. Relevant items were reverse-
scored so that higher overall scale scores represent higher levels of depressive
symptomatology. Scale scores can range from 0 to 60, with a total score of 16 or higher
indicative of clinically significant depressive symptoms [8]. We treated depressive
symptoms as a continuous variable. Cronbach’s alpha was 0.92 for the current study.
Interpersonal factors—Participants completed one item about perceived medication-
related adherence support from their family and their friends. Specifically, participants
indicated how often their family and friends provided support for taking their vasculitis
medications as prescribed. Responses ranged from 1=“does not do this” to 4=“does this a
lot.” Responses of “not applicable” were recoded as 1 to indicate that family or friends did
not provide that type of support. Higher scores reflected greater perceived adherence
support.
Medication non-adherence—The Vasculitis Self-Management Survey (VSMS)
medication adherence scale, which was developed specifically for use with vasculitis
populations, was used to measure non-adherence [23]. The VSMS asks respondents to
describe their medication-taking behavior during the past 4 weeks. The scale consists of
seven items measured on a five-point Likert scale; the response scale for six items ranges
from 1=“none of the time” to 5=“all of the time,” while the seventh item (percentage of
medication doses taken exactly as directed) ranges from 1=“0–24 %” to 5=“100 %.” The
VSMS medication adherence scale has demonstrated acceptable internal consistency
(Cronbach’s α=0.77) and test-retest reliability of 0.60 in a previous study of vasculitis
patients [23, 24]. Higher summary scores indicate greater average non-adherence for all
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medications the patient was taking to treat their vasculitis. Cronbach’s alpha was 0.89 in this
study.
Data analysis
All analyses were conducted using SAS v. 9.2. After calculating descriptive statistics
(means, standard deviations, skewness, kurtosis), bivariate Pearson correlations and
independent samples t tests, as appropriate, were used to determine whether the relationship
between medication non-adherence and demographic, clinical, regimen-related,
intrapersonal, and interpersonal factors was significant. We also report the percentage of
patients experiencing side effects for each type of medication as well as average medication
non-adherence for each type of medication (e.g., mycophenolate mofeitil, steroids). Due to
small cell sizes (i.e., low numbers of patients taking particular medications), we present
descriptive statistics rather than trying to determine whether there were statistically
significant differences in adherence for patients who experienced side effects versus did not
experience side effects.
Next, a linear regression model that included all significant (p<0.05) correlates of
medication adherence was examined to determine which baseline variables were significant
predictors of medication non-adherence at 3-month follow-up. Beta coefficients were
considered significant if p<0.05. We used linear regression, rather than logistic regression,
because the dependent variable (i.e., medication non-adherence summary score) was
continuous and had reasonable skewness and kurtosis values. Missing data were handled
with listwise deletion and, for multi-item scales, summary scores were treated as missing if
more than 25 % of the scale’s items were missing.
Results
Sample characteristics
Table 1 summarizes the characteristics of the final study sample (n=228). A majority of
participants were female (70 %), white (91 %), married or partnered (82 %), and had health
insurance (93 %). On average, participants were middle-aged and reported some college
education. Most patients had a diagnosis of GPA (59 %), but EGPA, microscopic
polyangiitis, and Takayasu arteritis patients were also represented in the sample. Patients
had been living with vasculitis for an average of 6.4 years. Regarding relapse/-flare status,
28 % of patients were experiencing a relapse or flare at the time of the baseline survey, and
13 % reported never experiencing a relapse or flare. An additional 29 % of patients had
experienced a relapse or flare within 1 year of taking the survey, while more than a year had
passed since experiencing a relapse for the remaining 29 % of patients. Patients perceived
their vasculitis as moderately severe and viewed family and friends as moderately
supportive. The average CES-D score was over 16.0, indicating depressive symptomology
with 55 % (n=126) having a score of 16 or greater. Overall, patients reported low levels of
medication non-adherence. Patient responses to individual medication non-adherence scale
items are presented in Table 2.
With regard to medications, patients most commonly took steroids (n=173; 75.9 %), co-
trimoxazole (n=83; 36.4 %), azathioprine (n=74; 32.5 %), and cyclophosphamide (n=63;
27.6 %). An overwhelming majority of patients (97.7 %) who were taking steroids reported
experiencing side effects. Similarly, 79.4 % of patients reported side effects from
cyclophosphamide. Approximately half of patients (47.3 %) reported azathioprine-related
side effects, and only 25.3 % of patients reported side effects due to co-trimoxazole (Table
3).
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Table 3 descriptively presents the mean medication non-adherence scores by type of
medication. On average, patients were least adherent to co-trimoxazole and cyclosprin and
were most adherent to steroids and azathioprine. With the exception of co-trimoxazole and
cyclophosphamide, patients who experienced drug-related side effects reported greater non-
adherence, on average, than patients who did not experience drug-related side effects.
Predictors of medication non-adherence
Younger age (r=−0.23, p<0.001), female gender (t(225)=−2.50, p=0.01), experiencing more
drug-related side effects (r=0.15,p=.02), and more depressive symptomatology (r=0.22,
p<0.001) were significantly associated with greater non-adherence at 3-month follow-up.
The relationship between greater perceived vasculitis severity and adherence trended toward
significance (r=0.12,p=0.07). Support variables and clinical characteristics were not
significantly associated with adherence.
In a linear regression model (Table 4) that included the significant correlates of non-
adherence described above (i.e., age, gender, side effects, depressive symptoms), only age
and depressive symptoms were significantly associated with medication non-adherence.
Specifically, younger patients and patients with more depressive symptoms were more non-
adherent.
Discussion
Adherence to vasculitis medications is complex and associated with a variety of factors,
including demographic, regimen-related, and intrapersonal factors. Overall, vasculitis
patients reported a high level of medication adherence. But even among this highly adherent
sample, patients who were younger and had more depressive symptoms reported worse
adherence to therapy at 3-month follow-up. Given that previous research has found that
perceived regimen complexity and interpersonal factors, such as adherence-related support
from physicians, predict medication adherence for vasculitis patients, attempts to improve
patient adherence should take a multifaceted ecological approach [13–15] by: (1) addressing
patients’ medication beliefs and behaviors, (2) enlisting partner support, and (3) improving
patient–provider communication about medications and medication side effects during
medical visits.
Previous research with patients who have diseases such as RA and gout have yielded mixed
results regarding the effects of age on medication adherence [7, 10]. To be specific, some
studies have found that older patients are more adherent than younger patients [9, 19, 20],
while others found no significant effects for age [10, 18]. In our sample, which had a mean
age of 51, younger patients were less adherent to their medications than older patients. There
are several possible explanations for this finding. First, younger patients have less
experience managing vasculitis medication regimens. Because adherence may improve as
patients develop and refine their medication management routines, younger patients may be
more at risk of non-adherence. Briesacher and associates found that a history of medication
use did not influence adherence for gout patients, so greater experience with taking
medications may not be the most likely explanation for the relationship between older age
and better adherence [19]. Alternatively, younger patients may have busier lifestyles that
interfere with medication-taking regimens; Park and colleagues partially attributed worse
adherence with younger RA patients to busy lifestyles [9]. Regardless of the potential
mediating mechanisms between age and adherence, providers should discuss medication-
related issues with younger patients to assess whether they are having difficulties managing
their medications.
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Interestingly, clinical characteristics were not significantly correlated with adherence.
Vasculitis patients are probably aware that their medications are critical to survival; hence;
they may have been adherent to their medications regardless of perceived disease severity or
relapse/remission status. For example, patients in remission may be just as motivated as
relapsing patients to take their medications. In the first case, patients in remission take
maintenance medications to avoid future relapse, whereas, in the second case, relapsing
patients take medications to induce remission. Either way, medications are generally
associated with positive outcomes (avoiding relapse or inducing remission). It is possible
that more objective measures of disease severity, such as disease activity measures (e.g.,
Birmingham vasculitis activity score [25]), may have been significantly associated with
patient adherence. Because objective and subjective measures of disease severity have been
associated with patient adherence in a large meta-analysis [26], both should be assessed
during medical visits. Additionally, future adherence studies should measure both objective
and patient-reported disease severity.
Over 97 % of patients who took steroids reported experiencing drug-related side effects.
Experience of drug-related side effects on the initial survey was significantly associated with
worse adherence at 3-month follow-up; however, this relationship did not remain significant
when adjusting for other factors. Side effects have been associated with worse adherence in
previous studies [2, 12, 16, 17, 27]; thus, providers should assess patients’ experiences with
medication side effects. We observed that patients who experienced side effects were less
adherent, on average, to six of eight vasculitis medication types than patients who did not
experience side effects. These findings suggest that providers should assist patients with
managing drug-related side effects since this may ultimately improve adherence.
Additionally, future research should obtain patient ratings for side effect severity as this
variable may be more strongly related to adherence than whether any side effect was
experienced.
In the multivariable regression model, baseline depressive symptoms predicted worse
adherence at 3-month follow-up. On average, patients in our sample reported a clinically
significant level of depressive symptoms [22], which has been documented in other samples
of vasculitis patients [28–30]. Given that depression also has been strongly associated with
non-adherence in the past [3], we believe that providers should evaluate patients for
depressive symptoms and specifically discuss adherence-related issues with vasculitis
patients who show clinical signs of depression.
Although patients received moderate amounts of adherence-related support from their
family and friends, support was not significantly associated with medication adherence at 3-
month follow-up. This finding contradicts previous studies that have found that regimen-
related support from friends and family is associated with better adherence [31]. We have
previously documented that adherence-related support from physicians has been associated
with better medication adherence [14, 15]; hence, vasculitis patients may prefer to receive
medication-related support from knowledgeable health professionals rather than less
knowledgeable friends and family [32]. Because many vasculitis patients believe that their
friends and family do not understand their illness, patients may be more likely to rely on
these sources for emotional and companionship support and turn to health providers for
disease-specific support [33].
This study possesses several limitations. First, we used a self-report measure of medication
adherence. Although the measure had been validated previously with vasculitis patients, it is
likely that patients overestimated their medication adherence [34]. This overestimation may
have biased our results toward the null; thus, we may not have been able to detect all
significant predictors of medication non-adherence. Additionally, patients reported overall
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adherence for all medications they were taking to treat their vasculitis; hence, we were
unable to look at medication-specific adherence. The use of a one-item measure of social
support is also a limitation. Future studies should use more comprehensive, validated
measures of social support. Second, generalizability was limited by our sample’s lack of
diversity, which was predominantly older, female, and white. Because the study surveys
were completed online, our sample may have been more motivated, better educated, and had
greater resources than the general vasculitis population; thus, our sample may have been
more adherent than the general population. Moreover, because some study participants were
recruited at patient conferences and from pools of patients who completed other vasculitis
studies, it is likely that our sample was more motivated and adherent than the general
population of vasculitis patients. Although our sample was highly adherent, it may be
impossible to recruit samples that include large numbers of non-adherent patients because
most vasculitis patients are probably aware that medication non-adherence is associated with
major morbidity and mortality. Third, self-reported diagnoses of vasculitis may not be
completely accurate; no studies have established the validity of self-reported vasculitis
diagnosis. For our analyses, we grouped multiple types of vasculitis patients together (e.g.,
Takayasu’s arteritis, EGPA, and MPA) in order to compare them to those with GPA; thus,
we cannot be sure if there were between-group differences in adherence. Fourth, we did not
control for the number of vasculitis medications that patients were taking. Future studies
should account for whether patients were taking multiple medications.
This study offers an overview of factors that may influence medication adherence for
vasculitis patients. Future studies should build upon these results by: (1) recruiting more
diverse samples of patients, (2) using more objective measures of medication adherence like
pharmacy refill records, and (3) including a broader array of predictors such as severity of
medication side effects. Providers should be aware that non-adherence may be an issue for
their vasculitis patients and should pay particular attention to younger patients who may
have difficulty incorporating a medication regimen into their lifestyles. Because gender, side
effects, and depressive symptoms were also associated with adherence, providers should
attempt to engage their vasculitis patients in discussions about adherence-related issues.
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Ecological model of medication adherence. Figure adapted from Clark 2003 [4]
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Table 1
Participant characteristics (n=228)
Characteristic Mean (SD) or % Range Skewness Kurtosis
Sociodemographic
Age 51.0 (13.3) 21.0–82.0 −0.1 −0.7
Male 30.3 %
White 91.3 %
Education (in years) 15.6 (2.8) 4.0–22.0 −0.2 1.7
Married or partnered 81.6 %
Have health insurance 93.4 %
Clinical
Self-reported vasculitis type
GPA (formerly Wegener’s) 59.2 %
EGPA (formerly Churg-Strauss) 12.7 %
Microscopic polyangiitis (MPA) 7.9 %
Takayasu arteritis (TA) 4.8 %
Other 15.4 %
Years with vasculitis 6.4 (6.2) 0.5–36.5 −2.0 5.2
Currently experiencing flare/relapse 28.4 %
Perceived vasculitis severity 4.5 (2.3) 1.0–10.0 0.1 −0.6
Regimen-related
Number of medication side effects 1.5 (1.1) 0.0–6.0 0.9 1.7
Perceived regimen complexity 3.0 (2.4) 1.0–10.0 1.2 0.8
Intrapersonal
Depressive symptoms 16.8 (12.2) 0.0–51.6 0.7 −0.4
Interpersonal
Family adherence-related supporta (n=186) 2.1 (1.1) 10–4.0 0.3 −1.3
Friend adherence-related supporta (n=173) 2.1 (1.2) 10–4.0 0.5 −1.3
Outcome
Medication non-adherenceb 1.7 (0.7) 10–44 1.2 1.6
a
Possible score range=1 to 4, higher scores reflect greater medication-related support
b
Possible score range=1 to 5, higher scores reflect greater non-adherence













Carpenter et al. Page 13
Table 2
Descriptive statistics for individual medication non-adherence scale items
Item Mean (SD)
I skipped a dose of my medicine. 1.49 (0.7)
I did not follow specific instructions for taking my medicines (for example, taking medicine with meals, drinking a certain
amount of water, timing of doses).
1.55 (0.9)
I could have done a better job following my health professionals’ recommendations for taking my medicine. 1.62 (1.0)
During the past 4 weeks, how often did you FAIL to take all of your recommended medicine(s) EXACTLY as directed? 1.67 (0.8)
During the past 4 weeks, how often did you find it easy to take your medicine(s) exactly as directed?a 4.32 (0.8)
During the past 4 weeks, how often did you have a hard time taking your medicine(s) exactly as directed? 1.60 (0.9)
During the past 4 weeks, what percentage of your recommended medicine(s) did you take exactly as directed?a,b 3.96 (1.2)




Responses range from 1=0–24 % to 5=100 %
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Table 4
Beta coefficients and p values for linear regression predicting medication non-adherence for vasculitis patient
(n=227)
Variable B(SE) p value
Age −0.01 (0.00) 0.01
Gender 0.14 (0.10) 0.16
Experienced drug-related side effects 0.03 (0.04) 0.44
Depressive symptomatology 0.01 (0.00) 0.02
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